Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Rating) – Equities researchers at HC Wainwright issued their Q1 2023 EPS estimates for Alpha Tau Medical in a note issued to investors on Monday, April 24th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings per share of ($0.05) for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Alpha Tau Medical’s current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Alpha Tau Medical’s Q2 2023 earnings at ($0.05) EPS, Q3 2023 earnings at ($0.06) EPS, Q4 2023 earnings at ($0.06) EPS, FY2023 earnings at ($0.22) EPS, Q1 2024 earnings at ($0.07) EPS, Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.27) EPS.
Alpha Tau Medical Price Performance
DRTS opened at $2.96 on Wednesday. Alpha Tau Medical has a fifty-two week low of $2.75 and a fifty-two week high of $12.50. The firm’s fifty day moving average price is $3.07 and its two-hundred day moving average price is $3.65. The company has a market capitalization of $204.62 million, a P/E ratio of -4.55 and a beta of 1.03.
Hedge Funds Weigh In On Alpha Tau Medical
Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new position in Alpha Tau Medical during the 2nd quarter worth $697,000. Ergoteles LLC bought a new stake in Alpha Tau Medical in the first quarter worth approximately $146,000. Renaissance Technologies LLC bought a new stake in Alpha Tau Medical in the third quarter worth approximately $111,000. Morgan Stanley increased its holdings in Alpha Tau Medical by 60.6% in the fourth quarter. Morgan Stanley now owns 18,603 shares of the company’s stock worth $59,000 after purchasing an additional 7,020 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new stake in Alpha Tau Medical in the first quarter worth approximately $40,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
Further Reading
- Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTS)
- Texas Instruments: Another Reason To Take Profits In Chip Stocks?
- 11 Best Growth Stocks to Buy Now
- How to Invest in GTE Technology
- Chipotle Mexican Grill Is Still A Tasty Investment
- Why Do Tech Stocks Go Down When Interest Rates Rise?
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
